Objective: To discuss the effectiveness and safety of Shenmai injection in treating patients with acute ST-segment elevation myocardial infarction (STEMI). Method: One hundred and twenty STEMI patients were selected from our hospital and randomly divided into the control group and the experimental group of 60 patients each. The patients in the control group received reteplase for injection. On the basis of the control group

the patients in the experimental group added Shenmai injection. The left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD)

the incidence of myocardial in farction recurrent

stable angina

congestive heart-failure

cardiac death

arrhythmia

peak time and recovery time of creatine kinase (CK) and CK isoenzyme-MB (CK-MB)

recovery situation and time of ecg ST segment

length of hospital stay and injection adverse reaction data of patients in both two groups were observed. Result: The clinical effect in the experiment group was superior to that in the control group (P<0.01). After treatment

LVEF in the experiment group was higher than that in the control group (P<0.05). Reperfusion rates of coronary in two groups were 78.33% and 88.33%

respectively

while there was no significant difference between two groups. The cumulative incidence rate of adverse cardiovascular events in the experiment group was 95%

which was higher than that of 63.33% in the control group (P<0.01). The average ST-segment elevation resolution was higher

recovery time of ST-segment was shorter

peak time and recovery time of CK and CK-MB were shorter in the experiment group than those in the experiment group (P<0.01). Conclusion: Shenmai injection combined with reteplase could improve cardiac function

relieve ischemia-reperfusion injury

ameliorate blood flow in the heart muscle

protect heart muscle and reduce the happening of bad cardiovascular event in treating STEMI.